Business Wire (Wed, 2-Sep 6:44 PM ET)
Globe Newswire (Wed, 2-Sep 5:34 PM ET)
Globe Newswire (Wed, 2-Sep 5:23 PM ET)
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
PRNewswire (Wed, 2-Sep 3:45 PM ET)
Globe Newswire (Wed, 2-Sep 3:20 PM ET)
Globe Newswire (Wed, 2-Sep 1:43 PM ET)
Business Wire (Wed, 2-Sep 1:43 PM ET)
Globe Newswire (Wed, 2-Sep 1:26 PM ET)
Stockholder Alert: Robbins LLP Informs Investors of the Hims & Hers Health, Inc. Class Action
Business Wire (Wed, 2-Sep 11:55 AM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of September 2, 2026, HIMS stock price climbed to $28.68 with 7,329,263 million shares trading.
HIMS has a beta of 2.28, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.08 to the broad based SPY ETF.
HIMS has a market cap of $6.69 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $753 million in Revenue and -$.37 earnings per share. This beat revenue expectation by $31 million and missed earnings estimates by -$.32.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): IJH, VTI, IWM, VB, VBK.
HIMS has underperformed the market in the last year with a return of -32.3%, while SPY returned +19.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HIMS shares. However, HIMS has outperformed the market in the last 3 month and 2 week periods, returning +3.3% and +4.7%, while SPY returned +1.1% and -0.3%, respectively. This indicates HIMS has been having a stronger performance recently.
HIMS support price is $26.94 and resistance is $29.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.
